Sun Pharma announces USFDA tentative approval for generic Uroxatral Extended Release ® tablets
Sun Pharmaceutical Industries Ltd announced that USFDA has granted its subsidiary a tentative approval for its Abbreviated New Drug Application (ANDA) for generic Uroxatral Extended Release ® tablets. These alfuzosin hydrochloride 10 mg tablets are therapeutically equivalent to Uroxatral Extended Release® tablets from Sanofi-Aventis. Alfuzosin hydrochloride tablets have annual sales of approximately USD 180 million in the US. Alfuzosin is an alpha 1 blocker for the treatment of the signs and symptoms of BPH.
Source: Sun Pharmaceuticals